Dana-Farber Cancer Institute, Inc.Months 1-6 study start up tasks, including submission of CIRB-approved protocol to local IRB and obtaining approval, establishing work-flow for image transfer…
$60,180
Dana-Farber Cancer Institute, Inc.The primary objective of this study is to evaluate if the combination of trivalent adenovirus-5 (Tri-Ad5) vaccines and IL-15 superagonist N-803 reduces the…
$23,777
Dana-Farber Cancer Institute, Inc.submission of CIRB-approved protocol to local IRB and obtaining approval, establishing work-flow for image transfer of mammorgrams to TRIAD within 4 days,…
$19,293
Dana-Farber Cancer Institute, Inc.Months 1-6 study start up tasks, including submission of CIRB-approved protocol to local IRB and obtaining approval, establishing work-flow for image transfer…
$111,620
The Institute For Cancer ResearchThe primary objective of this study is to evaluate if the combination of trivalent adenovirus-5 (Tri-Ad5) vaccines and IL-15 subperagonist N-803 reduces the…
$12,511
Fox Chase Cancer CenterA Phase IIB Clinical Trial of the Multitargeted Recombinant Adenovirus 5 (CEA/MUC1/BRACHYURY) Vaccines (TRI-AD5) and IL-15 Superagonist N-803 in Lynch…
$75,500
Ente Ospedaliero Ospedali Galliera DI GenovaThe primary interim objective will be to assess the safety of the experimental intervention based on the frequency of occurrence of a Dose Limiting Toxicity…
$241,994
Dana-Farber Cancer Institute, Inc.Dana-Farber Cancer Institute Serving as the Site PI/Co-Investigator, Dr. Ramona Lim and the Dana-Farber Cancer Institute will participate in a multicenter…
$170,750
Beckman Research Institute Of The City Of HopeDCP Protocol Number: INT21-05-01 Title of Study: A Phase IIB Clinical Trial of the Multitargeted Recombinant Adenovirus 5 (CEA/MUC1/BRACHYURY) Vaccines…
Dana-Farber Cancer Institute, Inc.Dana-Farber Cancer Institute Serving as the Site PI/Co-Investigator, Dr. Ramona Lim and the Dana-Farber Cancer Institute will participate in a multicenter…
$133,549
Beckman Research Institute Of The City Of HopeSubrecipient will participate in the design and conduct of a Phase IIa, Placebo-Controlled, Randomized Study of Daily Obeticholic Acid (OCA) to Reduce…
The Institute For Cancer ResearchDCP Protocol Number: INT21-05-01 Title of Study: A Phase IIB Clinical Trial of the Multitargeted Recombinant Adenovirus 5 (CEA/MUC1/BRACHYURY) Vaccines…
University Of Puerto Rico Medical Sciences CampusSubrecipient will participate in the design and conduct of a Phase Ib/II Clinical Trial of Nous-209 (vaccine) for Recurrent Neoantigen Immunogenicity and Cancer…
$9,706
Beckman Research Institute Of The City Of HopePrimary Objectives a) To evaluate the safety and tolerability of GAd20-209-FSPs (1 prime) and MVA-209-FSPs (1 boost) vaccination when administered as a single…
$1,760
Beckman Research Institute Of The City Of Hopea) To evaluate the safety and tolerability of GAd20-209-FSPs (1 prime) and MVA-209-FSPs (1 boost) vaccination when administered as a single agent…
$28,300
The Institute For Cancer ResearchTo assess the effect of Nous-209 vaccination on T cell immune profile and T cell receptor (TCR) repertoire in the peripheral blood of participants with LS. b)…
$122,996
University Of Puerto RicoTo evaluate the safety and tolerability of GAd20-209-FSPs (1 prime) and MVA-209-FSPs (1 boost) vaccination when administered as a single agent (monotherapy)…
$61,288
The Institute For Cancer ResearchTo assess the effect of Nous-209 vaccination on T cell immune profile and T cell receptor (TCR) repertoire in the peripheral blood of participants with LS. b)…
$51,341
Dana-Farber Cancer Institute, Inc.A Phase IIB Clinical Trial of the Multitargeted Recombinant Adenovirus 5 (CEA/MUC1/BRACHYURY) Vaccines (TRI-AD5) and IL-15 Superagonist N-803 in Lynch…
$228,275
Dana-Farber Cancer Institute, Inc.To evaluate the effect of treatment with OCA versus treatment with placebo on duodenal polyp burden (sum of polyp diameters) in participants with FAP.
$65,213
Show all 27
Quick answers
Who received award UG1CA242609?
UG1CA242609 was awarded to The Univeristy Of Texas M.d. Anderson Cancer Center by National Cancer Institute (National Institutes of Health) on August 15, 2019.
How much is award UG1CA242609 worth?
$24,487,810 has been obligated on UG1CA242609: $22,665,447 in federal funding and $1,822,363 in non-federal funding.